Physician profile
Chi Lai
NPI 1043238413
$17,612.31
in general payments reported to CMS, 2019-2025
14 companies · $700 in 2025
The $700 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $94.24 · 2021: $207 · 2022: $584 · 2023: $338 · 2024: $698 · 2025: $700.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,735.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,734.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $14,978.36 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $611.40 | 2020-2023 | Xifaxan |
| Vivus LLC | $464.36 | 2022-2025 | Pancreaze |
| Abbvie INC. | $432.10 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $368.98 | 2023-2025 | Voquezna |
| Novo Nordisk INC | $204.78 | 2025 | Wegovy |
| Aimmune Therapeutics, INC. | $172.98 | 2024-2025 | Zenpep, Vowst |
| E.R. Squibb & Sons, L.L.C. | $163.19 | 2024 | Zeposia |
| Pfizer INC. | $125.00 | 2025 | |
| Ardelyx, INC. | $22.91 | 2023 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $22.60 | 2025 | Iqirvo |
| Ferring Pharmaceuticals INC. | $16.81 | 2022 | |
| Celgene Corporation | $15.53 | 2024 | Zeposia |
| Allergan, INC. | $13.31 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chi Lai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.